<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2015-04-23" updated="2019-12-02">
  <drugbank-id primary="true">DB09041</drugbank-id>
  <drugbank-id>DB05058</drugbank-id>
  <name>Tavaborole</name>
  <description>Tavaborale is a novel, boron-based topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed due to *Trichophyton rubrum* or *Trichophyton mentagrophytes* infection. Tavaborole functions by inhibiting Leucyl-tRNA synthetase, or LeuRS, an essential fungal enzyme required for protein synthesis and for the catalysis of ATP-dependent ligation of L-leucine to tRNA(Leu).</description>
  <cas-number>174671-46-6</cas-number>
  <unii>K124A4EUQ3</unii>
  <average-mass>151.93</average-mass>
  <monoisotopic-mass>152.044488</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A7636</ref-id>
        <pubmed-id>25226015</pubmed-id>
        <citation>Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT: The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. 2014 Sep;13(9):1124-32.</citation>
      </article>
      <article>
        <ref-id>A7637</ref-id>
        <pubmed-id>25118637</pubmed-id>
        <citation>Markham A: Tavaborole: first global approval. Drugs. 2014 Sep;74(13):1555-8. doi: 10.1007/s40265-014-0276-7.</citation>
      </article>
    </articles>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated for the treatment of onychomycosis (a fungal infection) of the toenails due to &lt;i&gt;Trichophyton rubrum&lt;/i&gt; or &lt;i&gt;Trichophyton mentagrophytes&lt;/i&gt;. </indication>
  <pharmacodynamics>After a single dose, the mean (± standard deviation) peak concentration (Cmax) of tavaborole was 3.54 ± 2.26 ng/mL (n=21 with measurable concentrations, range 0.618-10.2 ng/mL, LLOQ=0.5 ng/mL), and the mean AUClast was 44.4 ± 25.5 ng*hr/mL (n=21). After 2 weeks of daily dosing, the mean Cmax was 5.17 ± 3.47 ng/mL (n=24, range 1.51­-12.8 ng/mL), and the mean AUCτ was 75.8 ± 44.5 ng*hr/mL. </pharmacodynamics>
  <mechanism-of-action>Tavaborole exerts its antifungal activity by blocking cellular protein synthesis through the formation of an adduct with cytoplasmic leucyl-aminoacyl transfer RNA (tRNA) synthetase.</mechanism-of-action>
  <toxicity>Tavaborole is generally well tolerated with most adverse events reported as mild and not related to treatment. Treatment related adverse events that occurred in &gt;1 % of participants include application site exfoliation, application site erythema, and application site dermatitis, and ingrown toenail. </toxicity>
  <metabolism>Tavaborole undergoes extensive metabolism. Metabolite profiling revealed trace levels of a sulfated-conjugate and a benzoic acid metabolite, consistent with the known biotransformation of tavaborole. </metabolism>
  <absorption>7.5%. Subungual onychomycosis is difficult to treat due to the poorly perfused location of the infection in the nailbed. To be effective, a topical treatment must penetrate the nail plate and reach the site of infection at a concentration sufficient to exert anti-fungal activity. Tavaborole was shown to produce anti-fungal effects after 5 days of topical administration. </absorption>
  <half-life>28.5 hr</half-life>
  <protein-binding/>
  <route-of-elimination>Primarily renal. </route-of-elimination>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as aryl fluorides. These are organic compounds containing the acyl fluoride functional group.</description>
    <direct-parent>Aryl fluorides</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Organohalogen compounds</superclass>
    <class>Aryl halides</class>
    <subclass>Aryl fluorides</subclass>
    <alternative-parent>Benzenoids</alternative-parent>
    <alternative-parent>Boronic acid esters</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Organic metalloid salts</alternative-parent>
    <alternative-parent>Organoboron compounds</alternative-parent>
    <alternative-parent>Organofluorides</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Oxaborole derivatives</alternative-parent>
    <alternative-parent>Oxacyclic compounds</alternative-parent>
    <substituent>1,2-oxaborole derivative</substituent>
    <substituent>Aromatic heteropolycyclic compound</substituent>
    <substituent>Aryl fluoride</substituent>
    <substituent>Benzenoid</substituent>
    <substituent>Boronic acid derivative</substituent>
    <substituent>Boronic acid ester</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>Organic metalloid salt</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organic salt</substituent>
    <substituent>Organoboron compound</substituent>
    <substituent>Organofluoride</substituent>
    <substituent>Organoheterocyclic compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Oxacycle</substituent>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="iupac">5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole</synonym>
    <synonym language="english" coder="iupac">5-Fluoro-2,1-benzoxaborol-1(3H)-ol</synonym>
    <synonym language="english" coder="inn/usan">Tavaborole</synonym>
  </synonyms>
  <products>
    <product>
      <name>Kerydin</name>
      <labeller>Pharma Derm, A Division Of Fougera Pharmaceuticals Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>10337-905</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Solution</dosage-form>
      <strength>43.5 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA204427</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Kerydin</name>
      <labeller>Anacor Pharmaceuticals, Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>55724-111</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2014-07-07</started-marketing-on>
      <ended-marketing-on>2015-06-04</ended-marketing-on>
      <dosage-form>Solution</dosage-form>
      <strength>43.5 mg/1mL</strength>
      <route>Topical</route>
      <fda-application-number>NDA204427</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Kerydin</name>
      <ingredients>Tavaborole</ingredients>
    </mixture>
    <mixture>
      <name>Kerydin</name>
      <ingredients>Tavaborole</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antifungal Agents</category>
      <mesh-id>D000935</mesh-id>
    </category>
    <category>
      <category>Antifungals for Dermatological Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antifungals for Topical Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Dermatologicals</category>
      <mesh-id>D003879</mesh-id>
    </category>
    <category>
      <category>Oxaborole Antifungal</category>
      <mesh-id/>
    </category>
    <category>
      <category>Protein Synthesis Inhibitors</category>
      <mesh-id>D011500</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Yeast and other Trichophyton or Microsporum fungi</affected-organism>
    <affected-organism>Dermatophytic fungi including Trichophyton, Microsporum and Epidermophyton</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Solution</form>
      <route>Topical</route>
      <strength>43.5 mg/1mL</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="D01AE24">
      <level code="D01AE">Other antifungals for topical use</level>
      <level code="D01A">ANTIFUNGALS FOR TOPICAL USE</level>
      <level code="D01">ANTIFUNGALS FOR DERMATOLOGICAL USE</level>
      <level code="D">DERMATOLOGICALS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB09041.pdf?1430164998</fda-label>
  <patents>
    <patent>
      <number>7582621</number>
      <country>United States</country>
      <approved>2009-09-01</approved>
      <expires>2027-11-26</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>7767657</number>
      <country>United States</country>
      <approved>2010-08-03</approved>
      <expires>2027-05-22</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
    <patent>
      <number>9566289</number>
      <country>United States</country>
      <approved>2017-02-14</approved>
      <expires>2026-08-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9549938</number>
      <country>United States</country>
      <approved>2017-01-24</approved>
      <expires>2026-08-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9566290</number>
      <country>United States</country>
      <approved>2017-02-14</approved>
      <expires>2026-08-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
    <patent>
      <number>9572823</number>
      <country>United States</country>
      <approved>2017-02-21</approved>
      <expires>2026-08-16</expires>
      <pediatric-extension>true</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions/>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>1.51</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.13e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>2.24</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>5-fluoro-3H-2,1-benzoxaborol-1-ol</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>151.93</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>152.044488</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>OB1OCC2=CC(F)=CC=C12</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C7H6BFO2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LFQDNHWZDQTITF-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>29.46</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>33.86</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.21</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>8.91</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-4.8</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>77942</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>11499245</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>310264989</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D10169</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>9674047</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>50370987</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tavaborole</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL443052</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/kerydin-side-effects-drug-center.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/tavaborole.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002395</id>
      <name>Cytosolic leucyl-tRNA synthetase</name>
      <organism>Yeast</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A7636</ref-id>
            <pubmed-id>25226015</pubmed-id>
            <citation>Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT: The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol. 2014 Sep;13(9):1124-32.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9HGT2" source="TrEMBL">
        <name>Cytosolic leucyl-tRNA synthetase</name>
        <general-function>Leucine-trna ligase activity</general-function>
        <specific-function/>
        <gene-name>CDC60</gene-name>
        <locus/>
        <cellular-location>Cytoplasm (By similarity)</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.44</theoretical-pi>
        <molecular-weight>125454.54</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="237561">Yeast</organism>
        <external-identifiers>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF293346</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9HGT2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>Q9HGT2_CANAX</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms/>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021988|Cytosolic leucyl-tRNA synthetase
MSGPVTFEKTFRRDALIDIEKKYQKVWAEEKVFEVDAPTFEECPIEDVEQVQEAHPKFFA
TMAYPYMNGVLHAGHAFTLSKVEFATGFQRMNGKRALFPLGFHCTGMPIKAAADKIKREV
ELFGSDFSKAPIDDEDAEESQQPAKTETKREDVTKFSSKKSKAAAKQGRAKFQYEIMMQL
GIPREEVAKFANTDYWLEFFPPLCQKDVTAFGARVDWRRSMITTDANPYYDAFVRWQINR
LRDVGKIKFGERYTIYSEKDGQACLDHDRQSGEGVGPQEYVGIKIRLTDVAPQAQELFKK
ENLDVKENKVYLVAATLRPETMYGQTCCFVSPKIDYGVFDAGNGDYFITTERAFKNMSFQ
NLTPKRGYYKPLFTINGKTLIGSRIDAPYAVNKNLRVLPMETVLATKGTGVVTCVPSDSP
DDFVTTRDLANKPEYYGIEKDWVQTDIVPIVHTEKYGDKCAEFLVNDLKIQSPKDSVQLA
NAKELAYKEGFYNGTMLIGKYKGDKVEDAKPKVKQDLIDEGLAFVYNEPESQVISRSGDD
CCVSLEDQWYIDYGEEVWLGEALECLKNMETYSKETRHGFEGVLAWMKNWAVTRKFGLGT
KLPWDPQYLVESLSDSTVYMAYYTIDRFLHSDYYGKKAGKFDIKPEQMTDEVFDYIFTRR
DDVETDIPKEQLKEMRREFEYFHPLDVRVSGKDLIPNHLTFFIYTHVALFPKRFWPRGVR
ANGHLLLNNAKMSKSTGNFMTLEQIIEKFGADASRIAMADAGDTVEDANFDEANANAAIL
RLTTLKDWCEEEVKNQDKLRIGDYDSFFDAAFENEMNDLIEKTYQQYTLSNYKQALKSGL
FDFQIARDIYRESVNTTGIGMHKDLVLKYIEYQALMLAPIAPHFAEYLYREVLGKNGSVQ
TSKFPRASKPVSKAILDASEYVRSLTRSIREAEGQALKKKKGKSDVDGSKPISLTVLVSN
TFPEWQDNYIELVRELFEQNKLDDNNVIRQKVGKDMKRGMPYIHQIKTRLATEDADTVFN
RKLTFDEIDTLKNVVEIVKNAPYSLKVEKLEILSFNNGETKGKNIISGEDNIELNFKGKI
MENAVPGEPGIFIKNVE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0004703|3294 bp
ATGAGTGGTCCTGTTACTTTTGAAAAGACATTTCGTAGAGATGCCTTAATCGATATAGAA
AAGAAATATCAAAAGGTATGGGCAGAAGAGAAAGTTTTTGAAGTTGATGCCCCAACTTTT
GAAGAATGTCCTATTGAAGATGTTGAACAAGTTCAAGAAGCACATCCAAAATTCTTTGCC
ACTATGGCTTATCCTTACATGAATGGTGTCTTGCACGCCGGTCATGCCTTTACATTGTCT
AAAGTTGAATTTGCAACTGGGTTCCAAAGAATGAATGGTAAGAGAGCATTATTCCCATTG
GGTTTCCATTGTACGGGTATGCCAATTAAAGCAGCTGCCGATAAAATCAAAAGAGAAGTT
GAATTGTTTGGATCTGATTTTTCTAAAGCTCCTATTGATGACGAAGATGCAGAAGAAAGC
CAACAACCAGCTAAAACCGAAACTAAAAGAGAAGATGTCACCAAATTCTCTTCCAAAAAA
TCCAAGGCTGCTGCCAAACAAGGTAGAGCCAAGTTCCAATATGAGATCATGATGCAATTA
GGAATCCCAAGAGAAGAAGTTGCCAAGTTTGCTAACACCGACTACTGGTTAGAGTTTTTC
CCACCATTGTGTCAAAAAGATGTAACTGCTTTTGGGGCTAGAGTTGATTGGAGACGTTCT
ATGATCACAACCGATGCTAATCCTTATTATGATGCATTTGTTAGATGGCAAATTAATAGA
TTGAGAGATGTTGGTAAAATTAAGTTTGGTGAAAGATATACCATTTATTCTGAAAAGGAT
GGCCAAGCATGTTTGGATCACGATAGACAATCTGGTGAAGGTGTTGGTCCACAAGAATAT
GTTGGTATAAAAATCAGATTAACTGATGTAGCACCACAAGCACAAGAACTTTTCAAGAAA
GAGAATCTCGATGTGAAGGAGAACAAAGTTTACTTGGTTGCTGCAACTTTAAGACCAGAA
ACTATGTATGGTCAAACTTGTTGTTTTGTGAGTCCAAAAATTGATTATGGTGTTTTTGAT
GCTGGTAATGGTGACTATTTCATTACCACTGAACGTGCTTTCAAAAATATGTCTTTCCAA
AACTTGACTCCGAAAAGAGGATATTATAAACCACTTTTCACTATCAATGGTAAGACATTG
ATTGGATCTCGAATTGATGCTCCATATGCTGTCAACAAAAACTTGAGAGTTTTGCCTATG
GAAACAGTTCTTGCAACCAAAGGTACTGGTGTGGTCACTTGTGTTCCATCAGATTCTCCA
GATGATTTTGTTACCACAAGAGACTTGGCCAATAAACCAGAGTACTATGGAATTGAAAAA
GACTGGGTACAAACAGATATTGTTCCTATTGTCCATACCGAAAAATACGGTGATAAGTGT
GCTGAGTTTTTGGTTAATGATTTGAAGATACAGTCACCAAAAGATTCTGTGCAGTTGGCC
AACGCCAAGGAATTGGCTTATAAAGAAGGTTTTTACAATGGTACTATGCTTATTGGTAAA
TACAAAGGTGATAAAGTTGAAGACGCCAAGCCTAAAGTCAAACAAGACTTAATTGATGAA
GGTCTTGCTTTTGTTTACAATGAACCAGAATCCCAAGTTATTTCTAGATCTGGTGATGAT
TGTTGTGTATCATTGGAAGATCAATGGTATATTGATTATGGTGAAGAAGTTTGGTTGGGT
GAAGCCTTAGAATGTCTTAAGAACATGGAAACATACTCCAAGGAAACCAGACATGGCTTC
GAAGGTGTTTTAGCTTGGATGAAGAACTGGGCTGTCACCAGAAAATTTGGTTTGGGTACT
AAATTGCCTTGGGATCCTCAATATTTGGTCGAATCTTTGTCAGATTCTACTGTCTATATG
GCTTATTATACTATTGATCGTTTCTTGCATTCAGATTATTACGGTAAGAAGGCAGGTAAG
TTCGACATTAAGCCAGAGCAAATGACTGATGAAGTATTTGATTACATCTTTACTCGTCGT
GATGACGTTGAAACTGACATTCCAAAGGAACAATTGAAGGAAATGAGAAGAGAGTTTGAA
TATTTTCACCCATTAGACGTCAGAGTTTCAGGAAAAGATTTAATCCCAAATCATTTGACA
TTCTTCATCTATACCCATGTCGCCTTGTTCCCAAAAAGATTTTGGCCAAGAGGTGTTAGA
GCCAACGGACATTTGTTGTTGAACAATGCTAAGATGTCCAAATCAACTGGTAACTTTATG
ACTTTAGAACAAATCATTGAAAAATTCGGAGCTGATGCCTCTAGAATTGCTATGGCCGAT
GCAGGTGACACTGTTGAAGATGCCAACTTTGACGAAGCCAATGCTAATGCTGCAATCTTG
AGATTGACAACTTTGAAAGATTGGTGTGAAGAAGAAGTGAAAAACCAAGACAAGTTAAGA
ATTGGTGACTACGATTCCTTCTTTGACGCTGCTTTTGAAAATGAAATGAATGATTTGATT
GAAAAGACTTACCAACAATACACTTTGAGTAATTACAAACAAGCATTGAAATCGGGATTG
TTTGATTTCCAAATCGCCAGAGATATTTATAGAGAAAGTGTAAACACAACAGGGATTGGT
ATGCACAAGGATCTTGTTTTGAAATACATTGAATACCAAGCATTGATGTTAGCTCCAATT
GCTCCTCATTTTGCCGAATACCTTTACAGAGAAGTTTTAGGTAAAAATGGAAGTGTTCAA
ACTAGCAAGTTCCCAAGAGCCTCAAAGCCTGTTTCCAAAGCTATTCTTGATGCTCTGGAA
TATGTCAGAAGCCTTACCAGATCTATCCGTGAAGCAGAAGGTCAAGCTTTGAAAAAGAAG
AAAGGAAAGTCTGATGTTGATGGGTCAAAACCAATCAGCTTGACAGTTTTGGTTTCCAAC
ACTTTCCCAGAATGGCAAGATAACTATATTGAACTTGTCAGAGAATTGTTTGAACAAAAC
AAGTTGGACGACAATAATGTTATAAGACAAAAGGTTGGCAAGGACATGAAACGTGGTATG
CCATACATCCACCAAATTAAAACTAGATTGGCAACTGAAGATGCTGACACTGTTTTCAAC
AGAAAATTGACTTTTGATGAAATCGATACATTGAAAAATGTTGTTGAAATTGTCAAGAAT
GCCCCATACTCTCTTAAAGTTGAAAAATTGGAGATTCTTAGTTTCAATAACGGTGAAACT
AAGGGGAAGAATATTATTAGTGGTGAAGACAATATTGAGCTCAATTTCAAGGGTAAAATA
ATGGAAAATGCTGTACCTGGTGAGCCTGGTATCTTTATTAAAAATGTCGAATAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF08264</identifier>
            <name>Anticodon_1</name>
          </pfam>
          <pfam>
            <identifier>PF00133</identifier>
            <name>tRNA-synt_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aminoacyl-tRNA editing activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>leucine-tRNA ligase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leucyl-tRNA aminoacylation</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>